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With the SAPIEN Valve*Dennis W. Kim, MD, PHDSEE PAGE 1819F or patients with signiﬁcant congenital heartdisease, the right ventricular outﬂow tract(RVOT) represents one of the most frequent
areas prone to surgical and transcatheter modiﬁca-
tion. Surgical reconstruction (transannular patches,
right ventricle to pulmonary artery conduits, bio-
prosthetic pulmonary valves) inevitability results in
the need for further intervention to restore valve
function due to reobstruction, progression of pulmo-
nary regurgitation, or a combination of both. Until
relatively recently, surgical palliative procedures
were the only alternatives. Philipp Bonhoeffer and
Alain Cribier simultaneously developed balloon-
expandable transcatheter valve systems in the 1990s
with Bonhoeffer et al. (1) reporting successful in-
human pulmonary valve implantation in 2000 and
Cribier et al. (2) reporting successful in-human aortic
valve implantation in 2002. Since those reports, there
has been rapid adoption of these techniques, which
speaks to the generalizability of these devices and im-
plantation systems for both the valves for which they
were initially developed as well as in other anatomic
positions. Intrepid physicians appreciate the promise
of these technologies, and additional applications are
quickly realized. The development of transcatheter
pulmonary valve replacement technologies repre-
sents a true game changer in the treatment of
valvular dysfunction. Recently, Cheatham et al. (3)
reported up to 7-year follow-up for 150 patients repre-
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up was 4.5 years (up to 7 years). Over this timeframe,
hemodynamic and clinical outcomes after Melody
valve implantation were promising, with pulmonary
valve function both in terms of stenosis and regurgi-
tation remaining largely unchanged from the time of
initial implantation in the absence of stent fracture
or endocarditis.In this issue of JACC: Cardiovascular Interventions,
Wilson et al. (4) report the Toronto experience using
the Edwards SAPIEN transcatheter valve system
(Edwards Lifesciences, Irvine, California) in the pul-
monary position. In this cohort, 25 patients were
evaluated, which qualiﬁes this as one of the largest
studies to date evaluating the SAPIEN valve in
the pulmonary position. In comparison, the initial
PARTNER (Placement of Aortic Transcatheter Valve)
trial enrolled 358 patients as part of the original report
(5). This is not the ﬁrst description of successful SA-
PIEN valve implantation in the pulmonary circulation.
In 2011, Kenny et al. (6) described early results of 36
patients undergoing percutaneous pulmonary valve
implantation in the prospective multi-institutional
COMPASSION (Congenital Multicenter Trial of Pul-
monic Valve Regurgitation Studying the SAPIEN
Interventional THV). Nevertheless, the experience of
the Toronto group represents the largest single-center
experience with SAPIEN pulmonary valve implanta-
tion reported to date.
Procedural success was high in this series (96%) as
was similarly described in the initial COMPASSION
study (97%). This speaks to the relative reliability of
the transcatheter technique for percutaneous pul-
monary valve replacement and to the reproducibility
of successful valve implantation in the hands of
experienced operators. That said, it should be noted
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1829that the SAPIEN systems were speciﬁcally developed
for aortic valve replacement where the retrograde
catheter course is typically more straightforward than
navigating the right heart through the tricuspid and
pulmonary valve positions with a relatively dilated
ventricular pathway interposed between the two. The
additional maneuverability capabilities of the SAPIEN
Retroﬂex and NovaFlex delivery systems do not reli-
ably help to navigate the tortuous right heart pathway
as much as for the retrograde left heart pathway for
which they were developed.
SAPIEN valves implanted in the report by Wilson
et al. included 23-, 26-, and 29-mm sizes, which allow
valve implantation in areas larger than can accom-
modate the Melody valve (generally up to a 24-mm
diameter). Two generations of SAPIEN valves were
included in this study, SAPIEN and SAPIEN XT, with
4 cases representing SAPIEN XT valves, 2 of which
were 29-mm valves. The SAPIEN XT is available in an
additional 29-mm size that is not available in the
original SAPIEN system and further extends the range
of a suitable implantation diameter. Implantation
sites included homograft conduits as well as bio-
prosthetic valve-in-valve implants, reﬂective of the
real-world application of transcatheter pulmonary
valve implantation. There was a notable exception of
implantation into the native RVOT, a situation that
the expanded size range of the SAPIEN valves might
seem suitable to accommodate.
Despite the differences in loading conditions for
valves in the pulmonary position compared with the
aortic position for which it was originally developed,
the SAPIEN valve appears to retain performance
durability over the midterm. In this series, functional
restoration of pulmonary valve function occurred
immediately, as judged by reduction of the mean
right ventricular-to-systemic pressure ratio, RV-PA
outﬂow gradient, and lack of signiﬁcant pulmonary
valve regurgitation. More importantly, the mean
follow-up duration of 3.5 years (up to 7.2 years) rep-
resents the longest follow-up cohort reported for the
SAPIEN valve in the pulmonary position, and valve
function continued to be maintained after implanta-
tion over this timeframe, much like for the Melody
valve. The issue of endocarditis after transcatheter
pulmonary valve implantation, particularly in rela-
tion to the Melody valve system, remains a vexing
one (7,8). Valve-associated endocarditis was not
experienced in this study; however, the overall im-
plantation numbers do not allow for adequate com-
parison with this emerging concern of the Melody
valve.
Pre-stenting of the landing zone for the SAPIEN
valve was performed in all cases. In the setting ofMelody valve implantation, pre-stenting is performed
to create a more trackable pathway for the valve de-
livery system and to reduce the dynamic compressive
load forces onto the relatively weaker stent of the
valve system. With the surgically modiﬁed RVOT
sandwiched between the rigid sternum anteriorly and
the beating heart posteriorly, the repetition of
compressive stress and deformation of the surgically
modiﬁed RVOT with each cardiac cycle is particularly
unique and potentially violent to hardware implanted
in this area. Valve-associated stent fracture is a
notable concern of the Melody valve system or for
primary stenting of the RV-PA pathway, which is
improved with routine pre-stenting of the implanta-
tion zone (3,9). Although stent fracture has not been
described for the SAPIEN valve in either the aortic or
pulmonary positions, pre-stenting with a covered
stent serves another unique function with the SAPIEN
system—the prevention of paravalvular leak due to
the relatively short sealing skirt within a geometri-
cally complex and potentially tortuous RV-PA
pathway. The Toronto investigators approached
this with pre-stenting using the balloon-expandable
polytetraﬂuoroethylene-covered Cheatham-Platinum
(CP) stent. Interestingly, this platinum-iridium stent
frame is the same as that used for the Melody valve.
The malleability of this covered stent allows for pre-
vention of paravalvular leak by long segment appo-
sition to the RVOT/conduit as well as allowing for
more options for SAPIEN valve implantation along the
length of the covered stent. Because of the robust
nature of the SAPIEN valve stent, maintenance of RV-
PA geometry in the area of the valve is less dependent
on the covered CP stent. However, fractures of the
covered CP stent in the adjacent areas from the SA-
PIEN valve were not systematically evaluated in
follow-up. Additionally, the use of a covered pre-
stent can protect against potentially catastrophic
conduit rupture during preparative dilation of the
implantation site.
In the United States, there are currently 2 per-
cutaneous valve systems that are most widely used
for percutaneous pulmonary valve replacement. The
Melody valve only recently achieved pre-market
approval by the U.S. Food and Drug Administration in
January 2015, a decade and a half after its initial in-
human implantation. Over these 15 years, this system
has largely remained unchanged. No other percuta-
neous valve systems have been developed speciﬁcally
for pulmonary valve rehabilitation. Over the same
timeframe, many more transcatheter aortic valve sys-
tems have been developed; 5 are available in the
United States, and an additional 2 are available in
Canada and Europe, with several more in various
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SAPIEN valve is already a multigenerational series with
additional reﬁnements made throughout its evolution.
Off-label uses of medical technologies in the pe-
diatric and adult congenital interventional realms are
not unusual. When one considers the typical in-
ventory present in congenital interventional cathe-
terization laboratories, it is sobering to realize how
little has been developed for speciﬁc application in
congenital cardiac interventions. For example, in the
United States, there are no balloon-expandable
stents speciﬁcally approved by the U.S. Food and
Drug Administration for use in the intracardiac,
pulmonary, or aortic vasculature, yet these pro-
cedures continue to be a mainstay of successful
therapies for vascular stenoses. The merits of ethical,
legal, and procedural challenges of off-label uses of
medical devices are not expounded on here other
than to reﬂect the current environment that pediatric
and adult congenital interventional cardiologistsface. On the way to successful restoration of pul-
monary valve function with the SAPIEN system, the
possibility exists for the use of a combination of
3 devices in the implantation zone in an off-label
fashion—a covered stent (for conduit rupture
prevention/treatment and prevention of paravalvular
leak), an additional bare metal bracing stent (for
durable primary or additional outﬂow tract aug-
mentation), and the SAPIEN valve. Although this
report by Wilson et al. does represent a relatively
large single-center experience, a multi-institutional
congenital interventional research infrastructure
needs to be established to develop cooperative and
fast-response investigations in this target-rich
environment.
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